KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $8.9 million.

  • Neogenomics' Cash from Operations fell 391.52% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year decrease of 879.59%. This contributed to the annual value of $7.0 million for FY2024, which is 45960.06% up from last year.
  • As of Q3 2025, Neogenomics' Cash from Operations stood at $8.9 million, which was down 391.52% from $20.3 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Cash from Operations registered a high of $20.3 million during Q2 2025, and its lowest value of -$29.0 million during Q1 2022.
  • Its 5-year average for Cash from Operations is -$4.4 million, with a median of -$3.7 million in 2022.
  • In the last 5 years, Neogenomics' Cash from Operations tumbled by 157661.6% in 2021 and then skyrocketed by 99741.6% in 2024.
  • Quarter analysis of 5 years shows Neogenomics' Cash from Operations stood at -$19.8 million in 2021, then surged by 81.37% to -$3.7 million in 2022, then soared by 582.61% to $17.8 million in 2023, then crashed by 44.89% to $9.8 million in 2024, then dropped by 9.35% to $8.9 million in 2025.
  • Its Cash from Operations stands at $8.9 million for Q3 2025, versus $20.3 million for Q2 2025 and -$25.3 million for Q1 2025.